Flax Pond Capital LLC Takes $364,000 Position in Compass Pathways PLC Sponsored ADR $CMPS

Flax Pond Capital LLC purchased a new position in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) during the fourth quarter, HoldingsChannel reports. The firm purchased 52,816 shares of the company’s stock, valued at approximately $364,000.

Several other large investors also recently modified their holdings of the company. Persistent Asset Partners Ltd purchased a new stake in Compass Pathways during the 4th quarter valued at approximately $38,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Compass Pathways in the fourth quarter worth $47,000. Advisory Services Network LLC bought a new position in shares of Compass Pathways during the third quarter worth $41,000. BIT Capital GmbH bought a new position in shares of Compass Pathways during the third quarter worth $54,000. Finally, MML Investors Services LLC purchased a new position in Compass Pathways during the fourth quarter valued at $69,000. Institutional investors own 46.19% of the company’s stock.

Analysts Set New Price Targets

CMPS has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a report on Monday, April 20th. Raymond James Financial reissued a “buy” rating on shares of Compass Pathways in a report on Friday, May 22nd. Jefferies Financial Group upgraded Compass Pathways to a “strong-buy” rating in a research report on Tuesday, May 5th. HC Wainwright reaffirmed a “buy” rating on shares of Compass Pathways in a report on Friday, May 22nd. Finally, UBS Group set a $18.00 target price on Compass Pathways in a research report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.36.

Compass Pathways Price Performance

Shares of CMPS opened at $12.53 on Friday. The firm has a fifty day moving average price of $10.22 and a 200-day moving average price of $7.84. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $1.69 billion, a P/E ratio of -3.98 and a beta of 2.50. Compass Pathways PLC Sponsored ADR has a 12-month low of $2.25 and a 12-month high of $14.76.

Compass Pathways (NASDAQ:CMPS) last posted its earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Equities research analysts expect that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current year.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.